CTE Sessions at EANM’11

EANM’11 – CTE Session VI

October 19, 2011, 09:30 – 10:45
Bone Cancer in SPECT/CT and PET/CT

Moderators: C. Pestean (Cluj-Napoca)


Speakers
extended
abstract
G. Cook (London):
The Value of PET/CT Imaging in the Evaluation of Primary and Secondary Skeletal Tumours
F. Cicone (Rome):
SPECT/CT Hybrid Imaging in the Evaluation of Skeletal Tumour Lesions
N. Guillaume (Basel):
Bone Cancer – a Future Perspective, new Tracers and new Directions in Diagnosis


Educational objectives:

Upon completion of this session the attendee will be able to:

  1. Identify the role of PET/CT in the evaluation of primary or metastatic bone lesions.
  2. Learn about the type of bone-specific PET tracers or tumour-specific PET tracers used in
    skeletal imaging.
  3. Identify the role of SPECT/CT in the diagnostic algorithm of skeletal lesions in oncology.
  4. Show the difference between conventional bone scintigraphy augmented with other
    diagnostic methods and SPECT/CT as a method of diagnosis.
  5. Find new directions and new perspectives in diagnostic algorithms and protocols in bone
    tumours considering also technetium shortage which was a critical issue in last period of
    time.
  6. Find the limits and the future aspect of hybrid PET/CT bone tumour imaging.


Summary:

Conventional bone scintigraphy in primary or metastatic bone lesions is an important tool in diagnosis and also in follow-up. But it is associated with low spatial resolution and often with low specificity. Even so bone scintigraphy remains the commonest method for evaluation or follow-up of bone metastatic disease. Due to its limitations, the perspective has changed and the interest for new hybrid methods is incremental.

With the advent of new hybrid methods as SPECT/CT and PET/CT the accuracy of diagnostic process has been increased having a better spatial resolution, a more clear anatomical localization, a higher specificity and sensitivity. The interest for tracers like [(18)F] fluoride (NaF) as a bone-specific tracer, or [(18)F] fluorodeoxyglucose and [(18)F] choline as tumour- specific tracers in diagnosis and follow-up has increased during recent years and are helpful alternatives to technetium-based methods especially at present when technetium shortage may be a critical problem.

It is very important to know how these hybrid methods can improve in a specific way the diagnostic process in bone cancer, even if we consider primary or metastatic lesions.


Key Words:

PET/CT, SPECT/CT, Bone Cancer, [(18)F] Fluoride (NaF), [(18)F] Fluorodeoxyglucose [(18)F] Choline, Bone Metastases

Back to top